Trial-based cost-effectiveness analyses (CEAs) are an important source of evidence in the assessment of health interventions. In these studies, cost and effectiveness outcomes are commonly measured at multiple time points, but some observations may be missing. Restricting the analysis to the participants with complete data can lead to biased and inefficient estimates. Methods, such as multiple imputation, have been recommended as they make better use of the data available and are valid under less restrictive Missing At Random (MAR) assumption. Linear mixed effects models (LMMs) offer a simple alternative to handle missing data under MAR without requiring imputations, and have not been very well explored in the CEA context. In this manuscrip...
Missing data are a frequent problem in cost-effectiveness analysis (CEA) within a randomised control...
Cost-effectiveness analyses (CEA) conducted alongside randomised trials provide key evidence for inf...
To obtain a better understanding of the pharmacokinetic and/or pharmacodynamic characteristics of an...
Trial-based cost-effectiveness analyses (CEAs) are an important source of evidence in the assessment...
INTRODUCTION: For the analysis of clinical effects, multiple imputation (MI) of missing data were sh...
OBJECTIVES: In trial-based economic evaluation, some individuals are typically associated with missi...
For studies with appreciable attrition in which one expects not only differences between individual ...
Cost effectiveness analysis (CEA) of randomised trials are an important source of evidence for infor...
BACKGROUND: Missing data are potentially an extensive problem in cost-effectiveness analyses con...
The authors would like to thank Professor Adrian Grant and the team at the University of Aberdeen (P...
The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Missing ...
Cost and effect data often have missing data because economic evaluations are frequently added onto ...
Longitudinal studies are useful in medical and health sciences research to examine effects associate...
Missing data are a common issue in cost-effectiveness analysis (CEA) alongside randomised trials and...
Missing outcome is a common occurrence in health research and the problem becomes more severe in lon...
Missing data are a frequent problem in cost-effectiveness analysis (CEA) within a randomised control...
Cost-effectiveness analyses (CEA) conducted alongside randomised trials provide key evidence for inf...
To obtain a better understanding of the pharmacokinetic and/or pharmacodynamic characteristics of an...
Trial-based cost-effectiveness analyses (CEAs) are an important source of evidence in the assessment...
INTRODUCTION: For the analysis of clinical effects, multiple imputation (MI) of missing data were sh...
OBJECTIVES: In trial-based economic evaluation, some individuals are typically associated with missi...
For studies with appreciable attrition in which one expects not only differences between individual ...
Cost effectiveness analysis (CEA) of randomised trials are an important source of evidence for infor...
BACKGROUND: Missing data are potentially an extensive problem in cost-effectiveness analyses con...
The authors would like to thank Professor Adrian Grant and the team at the University of Aberdeen (P...
The Author(s) 2014. This article is published with open access at Springerlink.com Abstract Missing ...
Cost and effect data often have missing data because economic evaluations are frequently added onto ...
Longitudinal studies are useful in medical and health sciences research to examine effects associate...
Missing data are a common issue in cost-effectiveness analysis (CEA) alongside randomised trials and...
Missing outcome is a common occurrence in health research and the problem becomes more severe in lon...
Missing data are a frequent problem in cost-effectiveness analysis (CEA) within a randomised control...
Cost-effectiveness analyses (CEA) conducted alongside randomised trials provide key evidence for inf...
To obtain a better understanding of the pharmacokinetic and/or pharmacodynamic characteristics of an...